Will China Healthcare Reform Drive Higher Rewards For Innovative Drugs?
This article was originally published in PharmAsia News
Executive Summary
BEIJING - China's sweeping healthcare reforms - designed to provide universal coverage for more than 1.3 billion citizens and build or upgrade medical care facilities across the country - are likely to have staggered benefits on varying industries over the next decade
You may also be interested in...
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China
Sweating The Little Things: European Companies Call On China to Overhaul Public Procurement System
They say misery loves company, so in one respect, biopharma and medical device companies can rest easy knowing that firms in seemingly every industry, from information technology firms to wind power equipment manufacturers, are struggling to make heads or tails of China's estimated $1 trillion public procurement market